The theory of cancer immune surveillance was formed in the late 20th century, suggesting that the immune system can identify and kill cancer cells.2 This idea was later confirmed upon detection of tumor antigen-specific CD8+ T cells in patients and led to the development of cancer immunotherapies such as immune checkpoint blockade.3–5 How can the immune system be activated by cancer cells in the absence of an infection? Here, CD8A is linked to cancer.